Novogyne Pharmaceuticals Acquires CombiPatch from Aventis

Estrogen/Progestin Skin Patch for Menopausal Symptoms

To Further Strengthen Women's Health Franchise



Apr 02, 2001, 01:00 ET from Novartis Pharmaceuticals Corporation

    EAST HANOVER, N.J. and MIAMI, April 2 /PRNewswire/ -- Novartis
 Pharmaceuticals Corporation and Noven Pharmaceuticals, Inc. announced today
 that their joint venture, Novogyne Pharmaceuticals, has acquired the U.S.
 rights to market CombiPatch (TM) (estradiol/norethindrone acetate transdermal
 system) from Aventis Pharmaceuticals, the U.S. pharmaceuticals business of
 Aventis Pharma AG.  The transdermal hormone replacement therapy will be
 marketed by Novogyne together with Vivelle(R) (estradiol transdermal system)
 and Vivelle-Dot(TM) (estradiol transdermal system).
     "CombiPatch will further strengthen our women's health franchise and is a
 perfect complement to Vivelle and Vivelle-Dot -- Novogyne's estrogen-only skin
 patches," said Robert C. Strauss, President of Novogyne.  "With the addition
 of CombiPatch, the Novogyne sales force now offers the most advanced and
 complete transdermal hormone replacement portfolio in the United States."
 
     About CombiPatch
     CombiPatch is a translucent, thin, adhesive-based matrix transdermal drug
 delivery system that is worn on the lower abdomen.  It releases both estradiol
 (an estrogen) and norethindrone acetate (a progestin) continuously upon
 application to the skin and delivers the medication in a steady and
 predictable manner.  CombiPatch is indicated for use in menopausal women with
 an intact uterus for the relief of moderate-to-severe vasomotor symptoms such
 as hot flashes, night sweats and vaginal dryness.  It is the first and only
 combination estrogen/progestin transdermal patch available for hormone
 replacement therapy in the United States.
 
     About Vivelle/Vivelle-Dot
     Vivelle and Vivelle-Dot are estrogen skin patches indicated for use in
 menopausal women for the relief of moderate-to-severe vasomotor symptoms such
 as hot flashes, night sweats and vaginal dryness.  Vivelle is also indicated
 for the prevention of postmenopausal osteoporosis.
 
     Safety Information
     In the three-month vasomotor clinical trial of CombiPatch, the most common
 adverse events were breast pain and dysmenorrhea.  The most commonly reported
 systemic adverse event with Vivelle-Dot was mild headache.  Systemic adverse
 events with Vivelle reported in clinical trials include headache, breast
 tenderness, fluid retention and back pain. Estrogens/progestins combined
 should not be used in women with known or suspected pregnancy, breast cancer,
 or estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, active
 thrombophlebitis or thromboembolic disorders, or a documented history of these
 conditions, or stroke.  Estrogens given without progestins have been reported
 to increase the risk of endometrial carcinoma in postmenopausal women.
 Progestins taken with estrogen drugs significantly reduce, but do not
 eliminate, the risk of endometrial cancer that is associated with the use of
 estrogen.
     More than one million women in the United States undergo menopause each
 year.  Clinical studies indicate that the addition of a progestin to an
 estrogen replacement regimen at least 12 days per cycle reduces, but does not
 eliminate, the incidence of endometrial hyperplasia and the potential risk of
 endometrial cancer in women with an intact uterus.
 
     About Noven
     Noven Pharmaceuticals, Inc. (Nasdaq: NOVN), headquartered in Miami,
 Florida, is a leader in the development of transdermal and transmucosal drug
 delivery systems and technologies.  Noven has developed and presently
 manufactures a series of leading-edge products, including the world's smallest
 estrogen transdermal delivery system and, the United States' only combination
 estrogen/progestin transdermal delivery system.  With a wide range of
 additional products in development, Noven is committed to becoming the world's
 premier developer, manufacturer, and marketer of transdermal and transmucosal
 drug delivery systems.  For more information on Noven, please visit
 www.noven.com.
 
     About Novartis
     Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation
 is an affiliate of the Novartis Group (NYSE:   NVS), a world leader in
 healthcare with core businesses in pharmaceuticals, consumer health, generics,
 eye-care, and animal health.  In 2000, the Group's ongoing businesses achieved
 sales of CHF 29.1 billion (USD 17.2 billion) and invested approximately CHF
 4.0 billion (USD 2.4 billion) in R&D.  Headquartered in Basel, Switzerland,
 Novartis employs about 67,600 people and operates in over 140 countries around
 the world.  For further information please consult http://www.novartis.com.
 
     For more information or a copy of the full prescribing information for
 CombiPatch, Vivelle or Vivelle-Dot, please visit www.combipatch.com,
 www.novogyne.com or telephone 1-888-NOW-NOVA.
 
 This release contains certain "forward-looking statements," relating to the
 companies respective businesses, which can be identified by the use of
 forward-looking terminology such as "will further strengthen," "will be
 marketed," "is a perfect complement to," or similar expressions or by
 discussions of strategy, plans or intentions.  Such statements include
 descriptions of the product to be introduced by the companies and anticipated
 customer demand for such product.  Such statements reflect the current views
 of the companies with respect to future events and are subject to certain
 risks, uncertainties and assumptions.  Many factors could cause the actual
 results, performance or achievements to be materially different from any
 future results, performances or achievements that may be expressed or implied
 by such forward-looking statements.  Some of these are uncertainties relating
 to product development, unexpected regulatory delays or government regulation
 generally, and competition in general, as well as factors discussed in the
 Form 20-F filed by Novartis AG, and the most current Form 10-K and Form 10-Q
 filed by Noven, with the Securities and Exchange Commission.  Should one or
 more of these risks or uncertainties materialize, or should underlying
 assumptions prove incorrect, actual results may vary materially from those
 described herein as anticipated, believed, estimated or expected.
 
     CONTACT:  Cathy J. Yarbrough, 973-781-5385, or Gina Moran, 973-781-5567,
 both of Novartis Pharmaceuticals Corporation; or Joseph C. Jones of Noven
 Pharmaceuticals, Inc., 305-253-1916/
 
 

SOURCE Novartis Pharmaceuticals Corporation
    EAST HANOVER, N.J. and MIAMI, April 2 /PRNewswire/ -- Novartis
 Pharmaceuticals Corporation and Noven Pharmaceuticals, Inc. announced today
 that their joint venture, Novogyne Pharmaceuticals, has acquired the U.S.
 rights to market CombiPatch (TM) (estradiol/norethindrone acetate transdermal
 system) from Aventis Pharmaceuticals, the U.S. pharmaceuticals business of
 Aventis Pharma AG.  The transdermal hormone replacement therapy will be
 marketed by Novogyne together with Vivelle(R) (estradiol transdermal system)
 and Vivelle-Dot(TM) (estradiol transdermal system).
     "CombiPatch will further strengthen our women's health franchise and is a
 perfect complement to Vivelle and Vivelle-Dot -- Novogyne's estrogen-only skin
 patches," said Robert C. Strauss, President of Novogyne.  "With the addition
 of CombiPatch, the Novogyne sales force now offers the most advanced and
 complete transdermal hormone replacement portfolio in the United States."
 
     About CombiPatch
     CombiPatch is a translucent, thin, adhesive-based matrix transdermal drug
 delivery system that is worn on the lower abdomen.  It releases both estradiol
 (an estrogen) and norethindrone acetate (a progestin) continuously upon
 application to the skin and delivers the medication in a steady and
 predictable manner.  CombiPatch is indicated for use in menopausal women with
 an intact uterus for the relief of moderate-to-severe vasomotor symptoms such
 as hot flashes, night sweats and vaginal dryness.  It is the first and only
 combination estrogen/progestin transdermal patch available for hormone
 replacement therapy in the United States.
 
     About Vivelle/Vivelle-Dot
     Vivelle and Vivelle-Dot are estrogen skin patches indicated for use in
 menopausal women for the relief of moderate-to-severe vasomotor symptoms such
 as hot flashes, night sweats and vaginal dryness.  Vivelle is also indicated
 for the prevention of postmenopausal osteoporosis.
 
     Safety Information
     In the three-month vasomotor clinical trial of CombiPatch, the most common
 adverse events were breast pain and dysmenorrhea.  The most commonly reported
 systemic adverse event with Vivelle-Dot was mild headache.  Systemic adverse
 events with Vivelle reported in clinical trials include headache, breast
 tenderness, fluid retention and back pain. Estrogens/progestins combined
 should not be used in women with known or suspected pregnancy, breast cancer,
 or estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, active
 thrombophlebitis or thromboembolic disorders, or a documented history of these
 conditions, or stroke.  Estrogens given without progestins have been reported
 to increase the risk of endometrial carcinoma in postmenopausal women.
 Progestins taken with estrogen drugs significantly reduce, but do not
 eliminate, the risk of endometrial cancer that is associated with the use of
 estrogen.
     More than one million women in the United States undergo menopause each
 year.  Clinical studies indicate that the addition of a progestin to an
 estrogen replacement regimen at least 12 days per cycle reduces, but does not
 eliminate, the incidence of endometrial hyperplasia and the potential risk of
 endometrial cancer in women with an intact uterus.
 
     About Noven
     Noven Pharmaceuticals, Inc. (Nasdaq: NOVN), headquartered in Miami,
 Florida, is a leader in the development of transdermal and transmucosal drug
 delivery systems and technologies.  Noven has developed and presently
 manufactures a series of leading-edge products, including the world's smallest
 estrogen transdermal delivery system and, the United States' only combination
 estrogen/progestin transdermal delivery system.  With a wide range of
 additional products in development, Noven is committed to becoming the world's
 premier developer, manufacturer, and marketer of transdermal and transmucosal
 drug delivery systems.  For more information on Noven, please visit
 www.noven.com.
 
     About Novartis
     Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation
 is an affiliate of the Novartis Group (NYSE:   NVS), a world leader in
 healthcare with core businesses in pharmaceuticals, consumer health, generics,
 eye-care, and animal health.  In 2000, the Group's ongoing businesses achieved
 sales of CHF 29.1 billion (USD 17.2 billion) and invested approximately CHF
 4.0 billion (USD 2.4 billion) in R&D.  Headquartered in Basel, Switzerland,
 Novartis employs about 67,600 people and operates in over 140 countries around
 the world.  For further information please consult http://www.novartis.com.
 
     For more information or a copy of the full prescribing information for
 CombiPatch, Vivelle or Vivelle-Dot, please visit www.combipatch.com,
 www.novogyne.com or telephone 1-888-NOW-NOVA.
 
 This release contains certain "forward-looking statements," relating to the
 companies respective businesses, which can be identified by the use of
 forward-looking terminology such as "will further strengthen," "will be
 marketed," "is a perfect complement to," or similar expressions or by
 discussions of strategy, plans or intentions.  Such statements include
 descriptions of the product to be introduced by the companies and anticipated
 customer demand for such product.  Such statements reflect the current views
 of the companies with respect to future events and are subject to certain
 risks, uncertainties and assumptions.  Many factors could cause the actual
 results, performance or achievements to be materially different from any
 future results, performances or achievements that may be expressed or implied
 by such forward-looking statements.  Some of these are uncertainties relating
 to product development, unexpected regulatory delays or government regulation
 generally, and competition in general, as well as factors discussed in the
 Form 20-F filed by Novartis AG, and the most current Form 10-K and Form 10-Q
 filed by Noven, with the Securities and Exchange Commission.  Should one or
 more of these risks or uncertainties materialize, or should underlying
 assumptions prove incorrect, actual results may vary materially from those
 described herein as anticipated, believed, estimated or expected.
 
     CONTACT:  Cathy J. Yarbrough, 973-781-5385, or Gina Moran, 973-781-5567,
 both of Novartis Pharmaceuticals Corporation; or Joseph C. Jones of Noven
 Pharmaceuticals, Inc., 305-253-1916/
 
 SOURCE  Novartis Pharmaceuticals Corporation

RELATED LINKS

http://www.us.novartis.com